LCB22A / LigaChem Biosci, GO Therap - LARVOL DELTA

Treatment of solid tumors with antibody drug conjugates targeting aberrant O-glycoproteins (AACR 2024) - "The ADCs based on GO-08 and GO-013 (LCB45A and LCB22A) demonstrated target-specific cytotoxicity invitro and in vivo with tumor elimination in breast and lung PDX models...Moreover, the ADCs selectively kill target cells in a human mixed organotypic cancer model without affecting healthy cells, indicating tolerability and safety. The combination of specificity of TACA targeting to differentiate ADC binding from healthy tissue and ConjuAll's tumor selective payload release promises to enable an excellent anti-cancer therapy."

ADC • IO biomarker • IO Companion diagnostic • Biliary Cancer • Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma • Triple Negative Breast Cancer

Status-agnostic therapy of breast cancer using antibodies targeting O-glycosylated proteins (AACR 2025) - "Additionally, the ADC selectively killed target cells in a human mixed organotypic cancer model without affecting healthy cells, indicating excellent tolerability and safety. By specifically targeting cancer-specific O-glycans expressed only in cancer tissues and employing a tumor-selective payload release mechanism, L100 ADC (LCB22A) offers a promising and safe therapeutic option for treating breast cancer while avoiding the on-target off-tumor toxicity that plague other ADC therapies."

Breast Cancer • Oncology • Solid Tumor